drugset
drugset / Trial / NCT02294396

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

NCT02294396 ↗

Phase 4 Completed 649 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.

Timeline

Start
2014-10-28
Primary completion
2016-09-07
Completion
2016-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Imidafenacin Small molecule 0.2 mg Oral
Subject Imidafenacin Small molecule 0.4 mg Oral
Subject Propiverine Small molecule 20 mg Oral
Subject Propiverine Small molecule 40 mg Oral
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral
Subject Tolterodine Small molecule 4 mg Oral
Background Mirabegron Other / unclassified 50 mg Oral

Indications

overactive bladder